Beyond aldosterone and renin: emerging biomarkers for diagnosing and subtyping primary aldosteronism

Clicks: 3
ID: 314969
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #181 of 220 articles by views in endocrine reviews

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 220 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Primary aldosteronism (PA) is the most common endocrine cause of high blood pressure, affecting more than 1 in 10 people with hypertension. Once considered rare, it has become a public health priority because undiagnosed PA confers significantly higher risks of stroke, myocardial infarction, heart failure, chronic kidney disease, and impaired quality of life. As a result, international guidelines now recommend routine screening for PA in all adults with hypertension. Despite this progress, diagnostic challenges remain. Conventional screening with plasma aldosterone, renin, and the aldosterone-to-renin ratio suffers from intra-individual variability and interference by medications, diet, posture, amongst other factors. Even when PA is diagnosed, distinguishing lateralizing from non-lateralizing adrenal disease is difficult. The current gold-standard test, adrenal vein sampling, is invasive, technically demanding, confined to specialized centers, and often yields inconclusive results. Emerging biomarker research offers new opportunities. Novel steroidomic-based approaches, such as steroid profiling, show promise for both diagnosis and subtyping. Circulating and urinary proteomic and metabolomic signatures are beginning to reveal molecular fingerprints of PA and its subtypes, while transcriptomic studies of adrenal tissue, circulating cells, and extracellular vesicles, along with circulating microRNAs, provide insights into pathophysiology and candidate diagnostic markers. Markers of end-organ damage are also emerging as complementary indicators of disease burden and treatment response. This review synthesizes current molecular and clinical biomarker research in PA, with an emphasis on their diagnostic, subtyping, and prognostic potential. By integrating traditional hormone assays with advances in multi-dimensional biomarker discovery, we highlight possibilities that may transform the diagnosis and management of PA.
Reference Key
openalex_W7162409584 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Renata Libianto, Charlotte L Uniacke, Peter J Fuller, Morag J Young, Jun Yang
Journal endocrine reviews
Year 2026
DOI
10.1210/endrev/bnag016
URL
https://doi.org/10.1210/endrev/bnag016
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.